Literature DB >> 28849371

MSA prions exhibit remarkable stability and resistance to inactivation.

Amanda L Woerman1,2, Sabeen A Kazmi1, Smita Patel1, Yevgeniy Freyman1, Abby Oehler1, Atsushi Aoyagi1,3, Daniel A Mordes4, Glenda M Halliday5,6,7, Lefkos T Middleton8, Steve M Gentleman9, Steven H Olson1,2, Stanley B Prusiner10,11,12.   

Abstract

In multiple system atrophy (MSA), progressive neurodegeneration results from the protein α-synuclein misfolding into a self-templating prion conformation that spreads throughout the brain. MSA prions are transmissible to transgenic (Tg) mice expressing mutated human α-synuclein (TgM83+/-), inducing neurological disease following intracranial inoculation with brain homogenate from deceased patient samples. Noting the similarities between α-synuclein prions and PrP scrapie (PrPSc) prions responsible for Creutzfeldt-Jakob disease (CJD), we investigated MSA transmission under conditions known to result in PrPSc transmission. When peripherally exposed to MSA via the peritoneal cavity, hind leg muscle, and tongue, TgM83+/- mice developed neurological signs accompanied by α-synuclein prions in the brain. Iatrogenic CJD, resulting from PrPSc prion adherence to surgical steel instruments, has been investigated by incubating steel sutures in contaminated brain homogenate before implantation into mouse brain. Mice studied using this model for MSA developed disease, whereas wire incubated in control homogenate had no effect on the animals. Notably, formalin fixation did not inactivate α-synuclein prions. Formalin-fixed MSA patient samples also transmitted disease to TgM83+/- mice, even after incubating in fixative for 244 months. Finally, at least 10% sarkosyl was found to be the concentration necessary to partially inactivate MSA prions. These results demonstrate the robustness of α-synuclein prions to denaturation. Moreover, they establish the parallel characteristics between PrPSc and α-synuclein prions, arguing that clinicians should exercise caution when working with materials that might contain α-synuclein prions to prevent disease.

Entities:  

Keywords:  Neurodegeneration; Propagation; Proteinopathies; Transmission models; α-synuclein

Mesh:

Substances:

Year:  2017        PMID: 28849371      PMCID: PMC5756500          DOI: 10.1007/s00401-017-1762-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  55 in total

1.  Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies.

Authors:  E Kuusisto; A Salminen; I Alafuzoff
Journal:  Neuroreport       Date:  2001-07-20       Impact factor: 1.837

Review 2.  Bioassays and Inactivation of Prions.

Authors:  Kurt Giles; Amanda L Woerman; David B Berry; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-08-01       Impact factor: 10.005

3.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

4.  Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery.

Authors:  C Bernoulli; J Siegfried; G Baumgartner; F Regli; T Rabinowicz; D C Gajdusek; C J Gibbs
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

5.  Inactivation of prions by acidic sodium dodecyl sulfate.

Authors:  David Peretz; Surachai Supattapone; Kurt Giles; Julie Vergara; Yevgeniy Freyman; Pierre Lessard; Jiri G Safar; David V Glidden; Charles McCulloch; Hoang-Oanh B Nguyen; Michael Scott; Stephen J Dearmond; Stanley B Prusiner
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

7.  Aβ seeds resist inactivation by formaldehyde.

Authors:  Sarah K Fritschi; Amarallys Cintron; Lan Ye; Jasmin Mahler; Anika Bühler; Frank Baumann; Manuela Neumann; K Peter R Nilsson; Per Hammarström; Lary C Walker; Mathias Jucker
Journal:  Acta Neuropathol       Date:  2014-09-06       Impact factor: 17.088

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

9.  Prion-like spreading of pathological α-synuclein in brain.

Authors:  Masami Masuda-Suzukake; Takashi Nonaka; Masato Hosokawa; Takayuki Oikawa; Tetsuaki Arai; Haruhiko Akiyama; David M A Mann; Masato Hasegawa
Journal:  Brain       Date:  2013-03-06       Impact factor: 13.501

10.  Structural and functional characterization of two alpha-synuclein strains.

Authors:  Luc Bousset; Laura Pieri; Gemma Ruiz-Arlandis; Julia Gath; Poul Henning Jensen; Birgit Habenstein; Karine Madiona; Vincent Olieric; Anja Böckmann; Beat H Meier; Ronald Melki
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  41 in total

1.  Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines.

Authors:  Amanda L Woerman; Abby Oehler; Sabeen A Kazmi; Jisoo Lee; Glenda M Halliday; Lefkos T Middleton; Steve M Gentleman; Daniel A Mordes; Salvatore Spina; Lea T Grinberg; Steven H Olson; Stanley B Prusiner
Journal:  Acta Neuropathol       Date:  2019-01-28       Impact factor: 17.088

Review 2.  Transmission of α-synuclein seeds in neurodegenerative disease: recent developments.

Authors:  Richard J Karpowicz; John Q Trojanowski; Virginia M-Y Lee
Journal:  Lab Invest       Date:  2019-02-13       Impact factor: 5.662

3.  Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.

Authors:  Zachary A Sorrentino; Yuxing Xia; Cory Funk; Cara J Riffe; Nicola J Rutherford; Carolina Ceballos Diaz; Amanda N Sacino; Nathan D Price; Todd E Golde; Benoit I Giasson; Paramita Chakrabarty
Journal:  Neurobiol Dis       Date:  2018-09-06       Impact factor: 5.996

4.  Familial Parkinson's point mutation abolishes multiple system atrophy prion replication.

Authors:  Amanda L Woerman; Sabeen A Kazmi; Smita Patel; Atsushi Aoyagi; Abby Oehler; Kartika Widjaja; Daniel A Mordes; Steven H Olson; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

5.  Is multiple system atrophy an infectious disease?

Authors:  Gregor Wenning; John Q Trojanowski; Horacio Kaufmann; Thomas Wisniewski; Walter A Rocca; Phillip A Low
Journal:  Ann Neurol       Date:  2018-01-14       Impact factor: 10.422

Review 6.  Synucleinopathies.

Authors:  Elizabeth A Coon; Wolfgang Singer
Journal:  Continuum (Minneap Minn)       Date:  2020-02

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

8.  Adsorption and decontamination of α-synuclein from medically and environmentally-relevant surfaces.

Authors:  Hanh T M Phan; Jason C Bartz; Jacob Ayers; Benoit I Giasson; Mathias Schubert; Keith B Rodenhausen; Negin Kananizadeh; Yusong Li; Shannon L Bartelt-Hunt
Journal:  Colloids Surf B Biointerfaces       Date:  2018-03-09       Impact factor: 5.268

Review 9.  Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nat Neurosci       Date:  2018-09-26       Impact factor: 24.884

Review 10.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.